Key Highlights

  • BCAL Diagnostics (ASX:BDX) traded at 7 cents during the 3 November 2026 session, down 14.63%.
  • Clinical validation of BREASTESTplus 2 was completed for women aged 30 and over, with a launch targeted for November 2026.
  • The company's strategic interest in Genetic Signatures rose to 18.46% after buying a further 18.75 million shares for $1.5 million.
  • The S&P/ASX 200 eased about 0.12% to 8,846.20 in the same session.

Share price performance on 3 November 2026

Shares of BCAL Diagnostics Limited (ASX:BDX) traded at 7 cents during the 3 November 2026 session, down 14.63%. Over the same session, the S&P/ASX 200 eased about 0.12%, or 10.30 points, to 8,846.20. BCAL is an Australian healthcare company focused on early cancer detection, with blood-based tests that it offers to clinicians and patients.

Latest development: September quarter report

BCAL released its quarterly activities report and Appendix 4C on 30 October 2026. The company completed clinical validation of BREASTESTplus 2 for women aged 30 and over across all breast densities. In the validation study the test showed a sensitivity of 80.3% and a specificity of 48.5% for early-stage breast cancer.

The company said the test is designed to support decisions alongside imaging and is not a standalone diagnostic. Accreditation and readiness work is under way ahead of a targeted November 2026 launch in Sydney, Melbourne and Brisbane.

BCAL also introduced Avantect Multicancer Early Detection at select Sydney and Melbourne locations, with national rollout planned through Sonic Healthcare and Healius. It said its portfolio now includes four blood-based early detection services.

Its strategic interest in Genetic Signatures increased to 18.46% after it acquired 18.75 million shares for $1.5 million, and Michelle Blackwell was appointed Chief Product Innovation Officer.

Sector context

Early cancer detection is a fast-growing area of diagnostics, but tests must show clinical validity and gain reimbursement and clinician acceptance before they reach routine use. Companies in this space often rely on research partnerships and registries to build real-world evidence.

Risks

The company's launch is subject to completion of accreditation and operational preparations. Sensitivity and specificity figures are from a validation study and may differ in routine use. The test is not intended to replace mammography, and adoption depends on clinicians and patients accessing it through participating sites.

What to watch next

Investors will be looking for the November 2026 launch of BREASTESTplus 2, the national rollout of Avantect Multicancer, and the next quarterly report.

The Final Word

BCAL Diagnostics shares traded lower on 3 November 2026. The company's 30 October update reported progress on its breast test and multicancer rollout, with the launch timetable still to be delivered.